Objective-Although vascular smooth muscle cells (VSMCs) provide the major structural integrity of atherosclerotic plaques, their origin has been questioned. In particular, although some studies identified plaque VSMCs originating from bone marrow or peripheral blood, their frequency is controversial and their function unknown. We used genetic tracking of cell fate through smooth muscle cell (SMC)-specific LacZ reporter activity and VSMC-selective apoptosis to investigate the frequency, distribution, and role of marrow-derived VSMCs in atherogenesis.
cellular matrix products comprise the major structural components of atherosclerotic plaques. In historical models of atherosclerosis, intimal VSMCs accumulate by migration from the media or proliferation from preexisting intima (where present), in part because of growth factors secreted by invading inflammatory cells. Thus, intimal VSMCs are derived from the vessel wall. 1 However, recent evidence suggests that some cells expressing VSMC markers in diverse vascular lesions may be bone marrow derived. Thus, some neointimal cells express hemopoietic cell markers, 2 including the macrophage scavenger receptor CD36, 3 and contribute to neointima formation. 4 Moreover, smooth muscle cell (SMC)like cells can be cultured from peripheral blood. [5] [6] [7] 
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Neointimal and medial bone marrow-derived cells expressing SMC markers have been found after mechanical injury, 4,8 -10 in allografts, and in humans. 11 However, the contribution of marrow or blood-derived SMC-like cells to neointimal lesions is controversial, depending on the model (vessel ligation, wire injury, cuff), 8 animal species, 12 bone marrow fraction, 13 SMC markers, and time point. In primary atherosclerosis, Metharom et al 11 and Caplice et al 14 showed that donor bone marrow provided up to 10% of VSMCs throughout the human atherosclerotic vessel. In contrast, Bentzon et al demonstrated that apolipoprotein E (ApoE) Ϫ/Ϫ mouse plaque VSMCs were only of vessel wall origin, 15 including cells repairing the plaque, 16 and that cells expressing progenitor markers such as sca-1 and c-kit/CD117 represent Ͻ1% of human intimal plaque cells. 17 Although the reported prevalence of bone marrow-derived SMC-like cells varies widely, 10, 15 their function is unknown. We recently described a mouse model whereby large artery medial and intimal VSMCs undergo selective apoptosis by transgenic expression of the human diphtheria toxin receptor (hDTR) from the minimal SM22␣ promoter, which is not expressed in endothelial cells or macrophages. 18 Diphtheria toxin (DT) administration has no effect on nontransgenic mice or cells, including after irradiation or bone marrow transplantation (BMT). 18, 19 Selective apoptosis demonstrated the protective role of VSMCs in both plaque development 20 and stability. 18 Using genetic tracking and selective apoptosis, we show that bone marrow-derived-SMC-like cells are present at low frequency in primary plaques in defined regions and that they promote atherogenesis.
Methods
Further details are given in the Supplemental Methods, available online at http://atvb.ahajournals.org.
Production of Bone Marrow-Derived SMC-Like Cells
Bone marrow was prepared as previously described 21 and is described in full in the Supplemental Methods. To differentiate bone marrow cells (BMCs) into SMCs, cells were cultured for a further 2 weeks in 5 ng/mL platelet-derived growth factor-BB (Biosource, Invitrogen).
Generation of Mice
Both C57Bl6/J SM22␣-hDTR mice and SM22␣-hDTR/ApoE Ϫ/Ϫ mice have been described previously. 18 Smooth muscle myosin heavy chain (SMMHC)/Cre recombinase 22 and ROSA26R/LacZ mice were each crossed with ApoE Ϫ/Ϫ mice and subsequently with each other. F1 SMMHC-Cre ϩ /ROSA26R ϩ /ApoE Ϫ/Ϫ mice were used for transplantation and BMC cultures.
Tissue Analysis
Histological, tissue, and cell X-Gal and morphometric analyses were as previously described. 19, 23 
Antibody Array
Custom-designed murine cytokine antibody arrays were used following the manufacturer's instructions (RayBiotech).
Collagen Synthesis
Collagen synthesis was assayed as described previously. 24
Cell Proliferation Assay
Cell proliferation was measured using a CyQuant NF cell proliferation kit (Invitrogen).
Statistical Analysis
Values were expressed as meanϮSEM. For groups showing similar variances, (eg, plaque area) group means were examined using a 2-sample unpaired Student t test. For nonnormal distributions (eg, immunohistological characterization), differences were examined using the nonparametric Mann-Whitney test. Significance was defined as PϽ0.05.
Results

Differentiation of Mouse BMCs Into SMC-Like Cells in Culture
hDTR and SMC marker expression were examined in unfractionated BMCs from SM22␣-hDTR mice. Day 0 BMCs showed minimal expression of SM22␣-hDTR, SMMHC, ␣-SMC actin (␣-SMA), calponin, or SM22␣ mRNAs ( Figure  1A ). However, SMC marker mRNAs were readily detected in separate BMC isolates after 21 days ( Figure 1A and 1B), with an expression broadly similar to that of mouse VSMCs on quantitative polymerase chain reaction ( Figure 1B ). Day 0 BMCs expressed minimal SMMHC, ␣-SMA, calponin, or SM22␣ protein, but these were expressed by day 21 ( Figure  1C and 1D).
Tracking of Bone Marrow-Derived SMC-Like Cells
Previous reports using SMC marker protein expression alone to define VSMCs demonstrated differing frequencies of bone marrow-derived cells expressing SMC markers in atherosclerosis. 10, 15 As SMC promoters are downregulated in plaque VSMCs, 25 reliance on SMC marker protein expression alone might underestimate bone marrow-derived SMC-like cells. We therefore transplanted bone marrow from SMMHC-Cre/ROSA26R/ApoE Ϫ/Ϫ mice into ApoE Ϫ/Ϫ mice to track SMC-specific promoter activity in vivo. In this system, any cre activity in differentiating smooth muscle-like cells generates LacZ-positive cells; subsequent SMMHC promoter downregulation does not lose transgene expression. 26 Aortic and coronary artery VSMCs in donor SMMHC-Cre/ ROSA26R/ApoE Ϫ/Ϫ mice demonstrated L␣cZ activity, indicating SMMHC promoter activity in mature VSMCs (Supplemental Figure I ). Some cardiomyocytes also expressed LacZ, consistent with transient cardiac SMMHC promoter expression during development, 22, 26 confirming that this system marks cells in adults. LacZ activity was absent in arteries of Cre-negative F1 littermates of SMMHC-Cre/ROSA26R/ ApoE Ϫ/Ϫ mice (Supplemental Figure I ) or marrow cells of any mouse (Supplemental Figure II) . Cultured day 0 SMMHC-Cre/ROSA26R/ApoE Ϫ/Ϫ BMCs did not demonstrate L␣cZ activity, but 85% of day 21 BMCs were Lac-Z positive (Supplemental Figure III) , consistent with concomitant SMMHC mRNA and protein expression ( Figure 1 ). Importantly, this demonstrates that SMMHC-cre/ROSA genetic tracking identifies far more cells than immunocytochemical staining for SMMHC protein.
To examine the contribution of marrow-derived SMC-like cells in atherosclerosis, ApoE Ϫ/Ϫ mice underwent irradiation, SMMHC-Cre/ROSA26R/ApoE Ϫ/Ϫ BMT, and fat feeding from 6 to 22 weeks (Supplemental Figure IV) . More than 95% of peripheral blood cells were of donor origin in ApoE Ϫ/Ϫ mice from 3 weeks after BMT (Supplemental Figure V ) up to 22 weeks. Neither bone marrow (Supplemental Figure II ) nor peripheral blood of transplanted mice showed LacZ-positive cells, but 0.7Ϯ0.14% (meanϮSEM, nϭ12 mice, 7420 cells) of cells in advanced plaques were LacZ-positive. Cells strongly positive for LacZ were located individually on the vessel surface or around and within the necrotic core (Figure 2A to 2C). Advanced plaque fibrous cap VSMCs were LacZ negative (Figure 2A and 2B). We found that 0.4Ϯ0.1% (meanϮSEM, nϭ12, 7420 cells) cells expressed both ␣-SMA and LacZ, seen mostly at the vessel surface ( Figure 2D and 2E). Necrotic core Lac-Z-positive cells were ␣-SMA negative ( Figure 2F ). We found that 0.2Ϯ0.03% of cells (meanϮSEM, nϭ12 mice) expressed both SMMHC and LacZ, seen on the vessel surface, but necrotic core or adventitial LacZ-positive cells were SMMHC negative (Supplemental Figure VI) . Fibrous cap SMMHC-positive cells did not show LacZ expression. LacZpositive cells were not found in plaques of control ApoE Ϫ/Ϫ mice after irradiation and SMMHC-Cre/ApoE Ϫ/Ϫ BMT, confirming that these manipulations alone do not generate LacZ activity (Supplemental Figure II) . We also examined plaques using double antibody labeling and high-resolution fluorescence microscopy with single-cell resolution to confirm coexpression of both markers. Cells expressing both LacZ and SMA could be identified both in plaques and media underlying plaques (Supplemental Figure VII) .
We also examined VSMC expression of CD105, Stro-1, CD44, CD90, Sca-1, and c-Kit/CD117 to indicate a progenitor cell origin. Unfractionated mouse BMCs increased CD105 and Stro-1 and reduced Sca-1 and c-kit/CD117 expression over 21 days in culture (Supplemental Figure  VIII) . By flow cytometry, 3.3% of day 21 BMCs and 27.4% of VSMCs expressed CD105. CD105 and Sca-1 were expressed on the plaque surface in a discontinuous endothelial cell-like monolayer and around adventitial microvessels. Stro-1 was expressed in foamy cells in superficial regions of early plaques. Cells expressing all markers were also seen as individual cells in the necrotic core. Of plaque cells, 0.1 to 0.4% (nϭ12 mice, nϭ7420 cells) expressed both ␣-SMA and either CD105, Stro-1, CD44, or CD90, located at the surface of early plaques or around the necrotic core (Supplemental Figure VIII) , further suggesting that most plaque VSMCs are not marrow derived and that most cells expressing "progenitor" markers in plaques are not VSMCs.
Apoptosis of SMC-Like Cells in Atherosclerotic Plaques
We used selective apoptosis of bone marrow-derived SMClike cells to determine their role in atherosclerosis. SM22␣-hDTR was expressed in day 21 but not day 0 BMCs ( Figure  1 ). Day 0 BMCs did not undergo apoptosis in response to DT, but Ͼ70% of day 21 BMCs underwent DT-induced apoptosis (Supplemental Figure IX) , confirming SM22␣-hDTR transgene expression and function in SM22␣-hDTR mice BMCs.
To prove that SMC-like cells undergo apoptosis in vivo, ApoE Ϫ/Ϫ mice underwent irradiation, SM22␣-hDTR/ ApoE Ϫ/Ϫ BMT, and fat-feeding from 6 to 22 weeks (Supplemental Figure IV ). Mice received 3 doses of 5 ng/g DT at 22 weeks (acute DT), with apoptosis examined by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)/cleaved caspase 3 expression 24 hours later. This regime induces apoptosis in CD11b-diphtheria toxin receptor (DTR) plaque macrophages and reliably estimates the number of DTR-expressing plaque cells. 19 In control (22 weeks) mice, 0.8Ϯ0.2% (meanϮSEM, nϭ10 mice) of plaque cells were TUNEL positive, similar to previous studies of advanced plaques 18 -20 ; apoptotic cells were located in the necrotic core but absent in fibrous caps ( Figure 3A and 3B ). Acute DT treatment increased apoptosis frequency to 1.9Ϯ0.3% (meanϮSEM, nϭ9, 7020 cells), with apoptotic cells now found superficially in early plaques ( Figure 3C to 3E) and the adventitia around microvessels ( Figure 3F ), although not in fibrous caps of established plaques ( Figure 3C and 3D). Cleaved caspase 3 frequencies also increased 2.5-fold by DT (0.6Ϯ0.1% to 1.5Ϯ0.2%, meanϮSEM, nϭ9) ( Figure 3G and 3H ). Acute apoptosis of marrow-derived SMC-like cells did not generate the intense local inflammation seen when vessel wall VSMCs undergo apoptosis 18 and did not change plaque size, total plaque cell number, Oil Red O area (to measure necrotic core size), or collagen content (Figure 4 ). Acute DT treatment slightly but significantly reduced total plaque ␣-SMA-positive VSMCs, but fibrous cap VSMC numbers were unchanged.
Effect of Apoptosis of Bone Marrow-Derived SMC-Like Cells in Atherogenesis
To examine the role of bone marrow-derived SMC-like cells in atherogenesis, 6-week old ApoE Ϫ/Ϫ mice underwent irradiation, SM22␣-hDTR/ApoE Ϫ/Ϫ BMT, and fat feeding from 6 to 22 weeks and were treated with 1 ng/g DT throughout (chronic DT) (Supplemental Figure IV) , a dose sufficient to induce VSMC apoptosis in SM22␣-hDTR/ApoE Ϫ/Ϫ mice, 20 or control. Serum lipids were similar between the two groups; serum interleukin (IL)-6 and IL-17 were slightly increased in DT-treated mice, whereas other cytokines were similar (monocyte chemotactic protein-1) or undetectable (IL-1RA, IL-10) (Supplemental Figure X) . Chronic DT administration significantly reduced total plaque area (Figures 4 and 5) . Total plaque or fibrous cap ␣-SMA percentages, and Oil Red O and Sirius Red areas were similar (Figure 4 ), suggesting that DT reduced both VSMCs and extracellular (lipid and collagen) components. However, DT significantly reduced macrophage (Mac-3) percentage areas (Figures 4 and 5) . MCP-1, intercellular adhesion molecule-1, IL-6, and IL-1RA were all expressed in a monolayer on the vessel surface, in superficial foam cells, and in the necrotic core (Supplemental Figure XI) . Chronic DT administration reduced the percentage of area of MCP-1 and intercellular adhesion molecule-1 (MCP-1, 12.5Ϯ1.2% versus 18.2Ϯ1.0%, PϽ0.05; intercellular adhesion molecule-1, 5.5Ϯ0.3% versus 8.1Ϯ0.9%, PϽ0.01, nϭ13), but IL-1RA and IL-6 expression were similar (23.6Ϯ2.1% versus 24.8Ϯ1.6% and 28.4Ϯ1.6% versus 32.3Ϯ3.5%, respectively). 
BMC-Derived SMC-Like Cells Stimulate Monocyte/Macrophage Migration
Apoptosis of SMC-like cells significantly reduced plaque size and macrophage content, despite there being relatively few marrow-derived SMC-like cells seen in advanced plaques and no serum antiinflammatory response. These findings suggest that SMC-like cells may signal to adjacent cells during atherogenesis, recruiting new inflammatory cells or increasing proliferation, migration, or matrix/collagen synthesis of adjacent vessel wall-derived VSMCs. Apoptotic SMC-like cells might also predominantly produce local antiinflammatory cytokines that reduce atherogenesis. Using antibody arrays ( Figure 6 and Supplemental Figure XII) , relative to VSMCs, day 21 BMCs had increased secretion of mostly pro-(MCP-1, granulocyte macrophage-colony-stimulating factor, CXCL16, IL-6) but also some antiinflammatory cytokines (IL-1RA and IL-10) and had reduced secretion of insulin-like growth factor-1. Apoptosis of day 21 BMCs increased macrophage-colony-stimulating factor, MCP-1, IL-1RA, granulocyte macrophage-colony-stimulating factor, IL-1␣, fractalkine, and insulin-like growth factor-1 secretion ( Figure 6B ), indicating that reduced plaque formation is not due to a local antiinflammatory effect after their apoptosis. Overall, day 21 BMC conditioned media promoted monocyte/ macrophage migration 3-fold versus day 0 BMC media, which was reduced by neutralizing antibodies to MCP-1 and IL-6 ( Figure 6C ), but had similar effects on macrophage proliferation (not shown). Conditioned media from day 0 or 21 BMCs induced Ͻ0.5% apoptosis (not shown). Both day 0 and day 21 BMC supernatants showed reduced collagen synthesis compared with VSMCs (Supplemental Figure XIII) ; however, BMC supernatants induced significantly greater collagen synthesis from vessel wall VSMCs compared with VSMC supernatants ( Figure 6D) , and both day 0 and day 21 BMCs markedly stimulated VSMC proliferation under serum-free conditions ( Figure 6E ).
Discussion
The finding of bone marrow-derived expressing SMC markers in atherosclerosis and other vascular diseases in multiple studies raised the concept that vascular "progenitor" cells arising from outside the vessel wall might occur in atherosclerosis. However, the role of these marrow-derived SMClike cells in atherosclerosis has not been studied, and their identification in primary atherosclerosis is difficult, 27 with previous studies showing between 0% and 60% of mouse intimal VSMCs being marrow derived. 10, 15 We used VSMC-specific genetic tracking and apoptosis to examine the frequency and role of marrow-derived SMC-like cells in atherosclerosis. DT administration to SM22␣-hDTR mice induces apoptosis only in medial and intimal VSMCs of large and medium-sized arteries. 18, 20 Importantly, plaque intimal VSMCs retain sufficient SM22␣-hDTR expression to undergo DT-induced apoptosis, including in the fibrous cap. 18, 20 SMMHC is considered the most specific and discriminating SMC marker. 25 Expression of SMMHC promoter-driven Cre recombinase occurs only in vascular and nonvascular SMCs in adult mice, 22, 26 apart from a small population of cardiomyocytes, possibly representing transient activation. 26 As Cre-mediated excision is irreversible, SMMHC promoter activity at any stage of differentiation generates LacZ activity in SMMHC-CreROSA26 mice. 22, 26 Thus, although the expression of DTR and LacZ may not be absolutely identical, DTR or LacZ expression in ApoE Ϫ/Ϫ mice receiving BMT of cells containing either transgene defines a marrow-derived cell that is (DTR) or has ever (LacZ) expressed SMC promoters.
Cultured BMCs increased expression of multiple SMC markers, which were not detectable at day 0, and activated SMC promoters, demonstrated by SM22␣-hDTR (BMCs from SM22␣-hDTR/ApoE Ϫ/Ϫ mice) and LacZ (BMCs from SMMHC-Cre/ROSA26R/ApoE Ϫ/Ϫ mice) expression. SM22␣-driven hDTR is active, as DT induced apoptosis of day 21 but not day 0 BMCs. Following SMMHC-Cre/ ROSA26R/ApoE Ϫ/Ϫ BMT into ApoE Ϫ/Ϫ mice, LacZpositive cells were not present in bone marrow or peripheral blood. However, 0.7% of plaque cells expressed Lac-Z, located mostly at the vessel surface and necrotic core. Fibrous caps of established plaques showed no LacZ-positive cells. We found that 0.4% of plaque VSMCs expressed ␣-SMA and LacZ, which could also be detected by double immunofluorescence at single-cell resolution. However, necrotic core LacZ-positive cells did not express ␣-SMA, suggesting that their SMC promoters are downregulated. Cells expressing ␣-SMA and CD105, CD90, CD44, or Stro-1 were also infrequent in plaques. The exquisite sensitivity of SM22␣-hDTR-expressing VSMCs to apoptosis means that increased VSMC apoptosis after acute DT treatment is a surrogate marker for transgene-expressing cells cells. 18 -20 DT increased apoptosis in plaques, mostly in superficial regions of early lesions, but not in caps of established plaques.
Taken together, our data support recent studies 15, 16 that marrow-derived SMC-like cells are infrequent in primary plaques and do not contribute to fibrous caps of established plaques. However, marrow-derived cells that express or have expressed the SMMHC promoter were present during atherogenesis. We suspect that the differences between our studies and others 15, 16 relate to different methods of tracking marrow cells (double labeling for simultaneous expression of green fluorescent protein and SMA versus single labeling for SMMHC-driven cre/LacZ) and the incremental nature of our genetic marker. The sensitivity and the incremental and more permanent nature of our lineage tracking system are reflected in the much higher percentage of day 21 SMMHC-cre/ROSA BMCs expressing LacZ activity compared with SMMHC by immunocytochemistry.
Chronic apoptosis of endogenous marrow-derived SMClike cells throughout atherogenesis reduced final plaque size. Previous studies show that marrow-derived SMC-like cells have a synthetic and secretory phenotype 10 ; their effect on atherogenesis may therefore be achieved by promoting inflammation or affecting adjacent resident VSMCs. Day 21 BMC-conditioned medium significantly increased monocyte/ macrophage migration via MCP-1 and IL-6 and promoted both collagen synthesis and proliferation in adjacent VSMCs, even in 0% fetal calf serum, indicating a highly potent action. In vivo, although SMC-like apoptosis reduced inflammation, consistent with the in vitro effect of these cells on macrophage migration, no changes in collagen or cell proliferation were observed, suggesting either that changes in the chronic, low-level nature of these processes in atherogenesis could not be detected or that these properties are not as important functions of these cells in vivo.
Our studies help define different functional roles for vessel wall VSMCs or marrow-derived SMC-like cells. Vessel wall VSMC apoptosis accelerates atherosclerosis or progression of established plaques, 20 induces multiple features of plaque vulnerability, 18 and promotes both local and systemic inflammation. 18 In contrast, marrow-derived SMC-like cell apoptosis retards atherogenesis, similar to monocyte/macrophage apoptosis in irradiation/transplant experiments, 19 with no reduction in fibrous cap cells and no local inflammation. These opposite effects indicate that reduced atherosclerosis observed here is not a nonspecific action of DT or of vessel wall cell apoptosis. Similarly, DT did not produce an antiinflammatory systemic response, and antibody arrays showed increased proinflammatory cytokines after BMC apoptosis, indicating that this is not a systemic effect due to apoptosis of marrow-derived SMC-like cells that have migrated to multiple tissues. Indeed, DT administration to ApoE Ϫ/Ϫ mice that do not express the DTR transgene does not result in smaller plaques compared with mice receiving control treatment. 20, 28 Interestingly, the distribution of marrow-derived SMC-like cells also suggests that they behave more like migrated mononuclear cells than vessel wall VSMCs. Marrow-derived SMC-like cells were absent from established fibrous caps but were located superficially in early macrophage-rich lesions or in the macrophage-rich necrotic core.
Although our LacZ and apoptosis data are highly consistent, there are some caveats to our interpretations. First, SMC-like cells in plaques might be underestimated, as not all adult aortic VSMCs express LacZ activity even in donor F1 SMMHC-Cre/ROSA26R mice, and only 85% of day 21 BMCs were LacZ positive. Reduced apoptosis of SMC-like cells expressing the SM22␣-hDTR transgene might occur if the minimal SM22␣ promoter is partly downregulated in atherosclerosis, 29 although SM22␣-hDTR remains functional in mouse plaques. 18, 20 However, we consider significant underestimation unlikely. We examined transplanted cells that express transgenes from 2 separate SMC promoters (SMMHC and SM22␣) activated when BMCs differentiate in vitro; there was both a quantitative and spatial agreement between the LacZ-positive cells and those undergoing DTinduced apoptosis after SM22␣-hDTR BMT. Myocardial LacZ-positive cells, where promoter expression is only transient, confirms the long-lasting and incremental nature of this marker. ␣-SMA downregulation in atherosclerosis might also underestimate LacZ/␣-SMA-positive VSMCs 29 ; however, 13% to 18% of all plaque cells and 45% of fibrous cap cells expressed ␣-SMA. However, our results relate only to marrow-derived SMC-like cells in primary atherosclerosis; these cells might comprise a different percentage and exert different effects in other vascular lesions, and SMC-like cells may be derived from progenitor populations in other organs or the vessels themselves. Finally, it is possible that irradiation and BMT may reduce SMC-like cell recruitment or differentiation. SMC progenitor cells are known to be recruited via stromal cell-derived factor-1␣/CXCR4-dependent mechanisms, 30, 31 and their differentiation depends on transforming growth factor-␤/notch signaling.
In summary, we demonstrate that bone marrow-derived SMC-like cells are present in primary atherosclerotic plaques but at low frequencies and do not contribute to fibrous cap VSMCs in advanced plaques. Marrow-derived SMC-like cells secrete cytokines that promote monocyte/macrophage migration, promote inflammation, and ultimately promote atherogenesis. These features, and their location, suggest that these cells behave more like macrophages than vessel wallderived VSMCs.
